Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals to Present at EORTC-NCI-AACR

Astex Pharmaceuticals to Present at EORTC-NCI-AACR

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals

Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals

Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors

Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors

Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union

Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia

DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia

Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program

Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program

Astex Pharmaceuticals to Participate on Oncology Panels at Upcoming Investor Conferences

Astex Pharmaceuticals to Participate on Oncology Panels at Upcoming Investor Conferences

Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients

Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients

Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration

Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration

Astex President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

Astex President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

Astex Pharmaceuticals Reports 2012 Second Quarter Financial Results

Astex Pharmaceuticals Reports 2012 Second Quarter Financial Results